Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH

December 12, 2022

https://www.globenewswire.com/news-release/2022/12/12/2572049/0/en/Affimed-Presents-Updated-Data-for-AFM28-Demonstrating-Efficient-Elimination-of-Leukemic-Stem-and-Progenitor-Cells-in-Combination-with-Allogeneic-NK-cells-in-Preclinical-Models-of-A.html

HEIDELBERG, Germany, Dec. 12, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq:AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster highlighting new preclinical data for its Innate Cell Engager (ICE®) AFM28 targeting CD123 and CD16A at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana.

Read more at globenewswire.com

Related news for (AFMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.